Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 plus FOLFOX4 versus placebo plus FOLFOX4 as first-line treatment for advanced hepatocellular carcinoma
CTR20191073Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started May 2019; status: active.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20191073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191073.